Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06251180 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06251180 · ClinicalTrials.gov record · last posted 2025-03-25

Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

StatusRecruiting
PhasePhase 1
Started2024-04-10
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 25, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
This is an open-label, multicentre Phase Ib study to evaluate the safety and preliminary efficacy of new generation Bruton Tyrosine Kinase inhibitor Rocbrutinib in combination to R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristin, Prednison) in adult patients with newly diagnosed, previously untreated B-cell Non-Hodgkin Lymphoma \[Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL) or Mantle Cell Lymphoma (MCL)\].

Amendment record 2 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 2 times since 2024-02-01; most recent amendment 2025-03-21. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-04-15
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT06251180
Lead Sponsor Guangzhou Lupeng Pharmaceutical Company LTD.
Conditions B-cell Non-Hodgkin Lymphoma
Enrollment 112 participants
Start Date 2024-04-10
Primary Completion 2025-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-25